Journal Mobile Options
Table of Contents
Vol. 30, Suppl. 3, 2012
Issue release date: January 2013
Dig Dis 2012;30(suppl 3):112–118
(DOI:10.1159/000342735)

Methotrexate: Underused and Ignored?

Herfarth H.H. · Long M.D. · Isaacs K.L.
Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, N.C., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

For more than a decade, methotrexate has been known to be an effective therapeutic agent in the treatment of steroid-dependent active Crohn’s disease. However, international data on medication utilization suggest that this drug is rarely used in clinical practice for an indication of Crohn’s disease. This review investigates the potential reasons for the underuse of methotrexate in patients with inflammatory bowel diseases.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Benchimol EI, Cook S, Erichsen R, et al: International Variation in Medication Prescription Rates in Elderly Patients with Inflammatory Bowel Disease. Gastroenterology 2012;142:S398–S399.

    External Resources

  2. Benchimol EI, Erichsen R, Cook S, et al: 1,146 International Variation in Medication Prescription Rates in Children with Inflammatory Bowel Disease. Gastroenterology 2012;142:S208.

    External Resources

  3. Saibeni S, Bollani S, Losco A, et al: The use of methotrexate for treatment of inflammatory bowel disease in clinical practice. Dig Liver Dis 2012;44:123–127.
  4. Kozarek RA, Patterson DJ, Gelfand MD, et al: Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989;110:353–356.
  5. Feagan BG, Rochon J, Fedorak RN, et al: Methotrexate for the treatment of Crohn’s disease. The North American Crohn’s Study Group Investigators. N Engl J Med 1995;332:292–297.
  6. Feagan BG, Fedorak RN, Irvine EJ, et al: A comparison of methotrexate with placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N Engl J Med 2000;342:1627–1632.
  7. Vandeputte L, D’Haens G, Baert F, et al: Methotrexate in refractory Crohn’s disease. Inflamm Bowel Dis 1999;5:11–15.
  8. Lemann M, Zenjari T, Bouhnik Y, et al: Methotrexate in Crohn’s disease: long-term efficacy and toxicity. Am J Gastroenterol 2000;95:1730–1734.
  9. Turner D, Grossman AB, Rosh J, et al: Methotrexate following unsuccessful thiopurine therapy in pediatric Crohn’s disease. Am J Gastroenterol 2007;102:2804–2812.
  10. Lemann M, Chamiot-Prieur C, Mesnard B, et al: Methotrexate for the treatment of refractory Crohn’s disease. Aliment Pharmacol Ther 1996;10:309–314.
  11. Mahadevan U, Marion JF, Present DH: Fistula response to methotrexate in Crohn’s disease: a case series. Aliment Pharmacol Ther 2003;18:1003–1008.
  12. Arora S, Katkov W, Cooley J, et al: Methotrexate in Crohn’s disease: results of a randomized, double-blind, placebo-controlled trial. Hepatogastroenterology 1999;46:1724–1729.
  13. Oren R, Moshkowitz M, Odes S, et al: Methotrexate in chronic active Crohn’s disease: a double-blind, randomized, Israeli multicenter trial. Am J Gastroenterol 1997;92:2203–2209.
  14. Visser K, Katchamart W, Loza E, et al: Multinational evidence-based recommendations for the use of methotrexate in rheumatic disorders with a focus on rheumatoid arthritis: integrating systematic literature research and expert opinion of a broad international panel of rheumatologists in the 3E Initiative. Ann Rheum Dis 2009;68:1086–1093.
  15. Visser K, van der Heijde D: Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature. Ann Rheum Dis 2009;68:1094–1099.
  16. Egan LJ, Sandborn WJ, Tremaine WJ, et al: A randomized dose-response and pharmacokinetic study of methotrexate for refractory inflammatory Crohn’s disease and ulcerative colitis. Aliment Pharmacol Ther 1999;13:1597–1604.
  17. Seideman P: Methotrexate-the relationship between dose and clinical effect. Rheumatology 1993;32:751–753.
  18. Montaudie H, Sbidian E, Paul C, et al: Methotrexate in psoriasis: a systematic review of treatment modalities, incidence, risk factors and monitoring of liver toxicity. J Eur Acad Dermatol Venereol 2011;25(suppl 2):12–18.
  19. Hamilton RA, Kremer JM: Why intramuscular methotrexate may be more efficacious than oral dosing in patients with rheumatoid arthritis. Br J Rheumatol 1997;36:86–90.
  20. Kurnik D, Loebstein R, Fishbein E, et al: Bioavailability of oral vs. subcutaneous low-dose methotrexate in patients with Crohn’s disease. Aliment Pharmacol Ther 2003;18:57–63.
  21. Balis FM, Mirro J Jr, Reaman GH, et al: Pharmacokinetics of subcutaneous methotrexate. J Clin Oncol 1988;6:1882–1886.
  22. Jundt JW, Browne BA, Fiocco GP, et al: A comparison of low-dose methotrexate bioavailability: oral solution, oral tablet, subcutaneous and intramuscular dosing. J Rheumatol 1993;20:1845–1849.
  23. Braun J, Kastner P, Flaxenberg P, et al: Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trial. Arthritis Rheum 2008;58:73–81.
  24. Oren R, Arber N, Odes S, et al: Methotrexate in chronic active ulcerative colitis: a double-blind, randomized, Israeli multicenter trial. Gastroenterology 1996;110:1416–1421.
  25. Herfarth HH, Osterman MT, Isaacs KL, et al: Efficacy of methotrexate in ulcerative colitis: failure or promise. Inflamm Bowel Dis 2010;16:1421–1430.
  26. Carbonnel F: Methotrexate: a drug of the future in ulcerative colitis? Curr Drug Targets 2011;12:1413–1416.
  27. Alfadhli AA, McDonald JW, Feagan BG: Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev 2005:CD003459.
  28. Patel V, Macdonald JK, McDonald JW, et al: Methotrexate for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2009:CD006884.
  29. Prefontaine E, Sutherland LR, Macdonald JK, et al: Azathioprine or 6-mercaptopurine for maintenance of remission in Crohn’s disease. Cochrane Database Syst Rev 2009: CD000067.
  30. Prefontaine E, Macdonald JK, Sutherland LR: Azathioprine or 6-mercaptopurine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2010:CD000545.
  31. Mate-Jimenez J, Hermida C, Cantero-Perona J, et al: 6-mercaptopurine or methotrexate added to prednisone induces and maintains remission in steroid-dependent inflammatory bowel disease. Eur J Gastroenterol Hepatol 2000;12:1227–1233.
  32. Ardizzone S, Bollani S, Manzionna G, et al: Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn’s disease: a randomised, investigator-blind study. Dig Liver Dis 2003;35:619–627.
  33. Stein RB, Hanauer SB: Comparative tolerability of treatments for inflammatory bowel disease. Drug Saf 2000;23:429–448.
  34. Searles G, McKendry RJ: Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol 1987;14:1164–1171.
  35. The effect of age and renal function on the efficacy and toxicity of methotrexate in rheumatoid arthritis. Rheumatoid Arthritis Clinical Trial Archive Group. J Rheumatol 1995;22:218–223.
  36. Salliot C, van der Heijde D: Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research. Ann Rheum Dis 2009;68:1100–1104.
  37. Wolfe F, Michaud K: Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 2004;50:1740–1751.
  38. Lindsay K, Fraser AD, Layton A, et al: Liver fibrosis in patients with psoriasis and psoriatic arthritis on long-term, high cumulative dose methotrexate therapy. Rheumatology (Oxford) 2009;48:569–572.
  39. Kalb RE, Strober B, Weinstein G, et al: Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009;60:824–837.
  40. Thomas JA, Aithal GP: Monitoring liver function during methotrexate therapy for psoriasis: are routine biopsies really necessary? Am J Clin Dermatol 2005;6:357–363.
  41. Kremer JM, Alarcon GS, Lightfoot RW Jr, et al: Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology. Arthritis Rheum 1994;37:316–328.
  42. Te HS, Schiano TD, Kuan SF, et al: Hepatic effects of long-term methotrexate use in the treatment of inflammatory bowel disease. Am J Gastroenterol 2000;95:3150–3156.
  43. Fraser AG, Morton D, McGovern D, et al: The efficacy of methotrexate for maintaining remission in inflammatory bowel disease. Aliment Pharmacol Ther 2002;16:693–697.
  44. Fournier MR, Klein J, Minuk GY, et al: Changes in liver biochemistry during methotrexate use for inflammatory bowel disease. Am J Gastroenterol 2010;105:1620–1626.
  45. Kozarek RA: Long-term treatment of Crohn’s disease with methotrexate, or, why’s a nice drug like you still a wannabe in the treatment of inflammatory bowel disease? Am J Gastroenterol 2000;95:1619–1620.
  46. Kappelman MD, Rifas-Shiman SL, Porter CQ, et al: Direct health care costs of Crohn’s disease and ulcerative colitis in US children and adults. Gastroenterology 2008;135:1907–1913.
  47. Fallowfield L, Atkins L, Catt S, et al: Patients’ preference for administration of endocrine treatments by injection or tablets: results from a study of women with breast cancer. Ann Oncol 2006;17:205–210.
  48. Dubinsky M, Abraham B, Mahadevan U: Management of the pregnant IBD patient. Inflamm Bowel Dis 2008;14:1736–1750.
  49. French AE, Koren G: Effect of methotrexate on male fertility. Can Fam Physician 2003;49:577–578.
  50. Dignass A, Assche GV, Lindsay JO, et al: The second European evidence-based Consensus on the diagnosis and management of Crohn’s disease: current management. J Crohn Colitis 2010;4:28–62.
  51. Lichtenstein GR, Abreu MT, Cohen R, et al: American Gastroenterological Association Institute Technical Review on Corticosteroids, Immunomodulators, and Infliximab in Inflammatory Bowel Disease. Gastroenterology 2006;130:940–987.
  52. Lichtenstein GR, Hanauer SB, Sandborn WJ: Management of Crohn’s disease in adults. Am J Gastroenterol 2009;104:465–483.
  53. Long MD, Martin C, Pipkin CA, et al: Risk of melanoma and non-melanoma skin cancer among patients with inflammatory bowel disease. Gastroenterology 2012;143:390–399.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50